Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVRL1 | P37023 | 10/20 | 0.62 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.41 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.38 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.38 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14488019 | 0.93 | ACVRL1 (0.64) | ACVRL1FGFR1FGFR3MAP4K4PIK3CD | |
| SCHEMBL14488101 | 0.86 | ACVRL1 (0.65) | ACVRL1FGFR1FGFR3MAP4K4PIK3CD | |
| SCHEMBL59608 | 0.82 | ACVRL1 (0.64) | ACVRL1FGFR1FGFR3PIK3CDKDM4E | |
| SCHEMBL14327080 | 0.82 | ACVRL1 (0.47) | ACVRL1FGFR1MAP4K4PIK3CDKDM4E | |
| SCHEMBL14888176 | 0.81 | ACVRL1 (0.46) | ACVRL1FGFR1FGFR3PIK3CDKDM4E | |
| SCHEMBL58280 | 0.80 | PIK3CD (0.46) | ACVRL1FGFR1FGFR3MAP4K4PIK3CD | |
| SCHEMBL65456 | 0.78 | ACVRL1 (0.59) | ACVRL1FGFR1FGFR3MAP4K4PIK3CD | |
| SCHEMBL14488361 | 0.78 | ACVRL1 (1.00) | ACVRL1 | |
| SCHEMBL16011367 | 0.77 | ACVRL1 (0.51) | ACVRL1FGFR1FGFR3MAP4K4PIK3CD | |
| SCHEMBL5137764 | 0.77 | ACVRL1 (0.46) | ACVRL1FGFR1FGFR3PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2726482-B1 | HYDROXYMETHYLARYL-SUBSTITUTED PYRROLOTRIAZINES AS ALK1 INHIBITORS | BAYER IP GMBH (DE) | 2016-07-20 | — | — | EP | disclosed |
| CN-103764657-B | The pyrrolo-triazine replacing as the methylol aryl of ALK1 inhibitor | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-05-25 | — | — | CN | disclosed |
| US-9040691-B2 | Hydroxymethylaryl-substituted pyrrolotriazines as ALK1 inhibitors | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-05-26 | — | — | US | disclosed |
| US-9040691-B2 | Hydroxymethylaryl-substituted pyrrolotriazines as ALK1 inhibitors | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-05-26 | — | — | US | disclosed |
| US-9040691-B2 | Hydroxymethylaryl-substituted pyrrolotriazines as ALK1 inhibitors | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-05-26 | — | — | US | disclosed |
| US-20140256718-A1 | HYDROXYMETHYLARYL-SUBSTITUTED PYRROLOTRIAZINES AS ALK1 INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-09-11 | — | — | US | disclosed |
| US-20140256718-A1 | HYDROXYMETHYLARYL-SUBSTITUTED PYRROLOTRIAZINES AS ALK1 INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-09-11 | — | — | US | disclosed |
| US-20140256718-A1 | HYDROXYMETHYLARYL-SUBSTITUTED PYRROLOTRIAZINES AS ALK1 INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-09-11 | — | — | US | disclosed |
| CN-103764657-A | Hydroxymethylaryl-substituted pyrrolotriazines as ALKL inhibitors | BAYER IP GMBH | 2014-04-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256718-A1 | HYDROXYMETHYLARYL-SUBSTITUTED PYRROLOTRIAZINES AS ALK1 INHIBITORS | ALK, FLT1, ACVR1 | ACVRL1 4/4885FGFR1 16/4885FGFR3 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.